Like popcorn in a pan, data with late-stage drugs for nonalcoholic steatohepatitis (NASH) will burst forth from a series of drug developers, and Wall Street is hard pressed to figure out which treatment – or combination thereof – might work best. But that hasn't stopped them from trying. Read More
For many drugs with targets in the central nervous system, it may not be the neurology target that keeps the drugs from succeeding in clinical trials, but the ability of the drug to get past the blood-brain barrier in high enough concentration to be effective. Read More
